Lexeo Therapeutics, Inc. announced it has entered into a common stock purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 6,278,905 shares of its common stock at an issue price of $15.13 per share for gross proceeds of $95,000,000 on March 11, 2024. the transaction will include participation from Braidwell LP, Adage Capital Partners LP, RA Capital Management, Surveyor Capital, Eventide Asset Management and Novo Holdings A/S. The transaction is expected to close on March 13, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.01 USD | -26.08% |
|
-20.43% | -3.06% |
Jul. 15 | Sector Update: Health Care Stocks Retreat Monday Afternoon | MT |
Jul. 15 | Lexeo Shares Tumble Despite 'Positive' Data in Trials of Gene Therapy Candidate for Cardiac Disorder | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.06% | 580M | |
+22.15% | 46.55B | |
+45.94% | 41.84B | |
-2.37% | 40.84B | |
+33.84% | 32.95B | |
-6.35% | 28.27B | |
+20.42% | 27.78B | |
+48.83% | 14.26B | |
+45.00% | 13.69B | |
+0.06% | 12.18B |
- Stock Market
- Equities
- LXEO Stock
- News Lexeo Therapeutics, Inc.
- Lexeo Therapeutics, Inc. announced that it expects to receive $94.999833 million in funding